A
Avalo Therapeutics, Inc. (AVTX)
NCM – Real Time Price. Currency in USD
19.94
-0.31 (-1.53%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
19.94
-0.31 (-1.53%)
At close: May 12, 2026, 4:00 PM EDT
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1β-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Barbara S. Slusher Ph.D. | Founder and Member of Scientific Advisory Board |
| Dr. Dino C. Miano Ph.D. | Senior Vice President of CMC & Technical Operations |
| Dr. Garry A. Neil M.D. | President, CEO & Director |
| Dr. Mittie Doyle FACR, M.D. | Chief Medical Officer |
| Dr. Solomon H. Snyder M.D. | Founder and Chairman of Scientific Advisory Board |
| Mr. Christopher Ryan Sullivan CPA | CFO & Head of Investor relations |
| Mr. Paul C. Varki J.D., M.P.H | Chief Legal Officer |
| Mr. Taylor Boyd | Chief Business Officer |
| Ms. Ashley Ivanowicz | Senior Vice President of Human Resources |
| Ms. Jennifer Riley | Chief Strategy Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | tm2613717d1_8k.htm |
| 2026-04-28 | 8-K | avtx-20260426.htm |
| 2026-04-10 | DEFA14A | defa14acombined.htm |
| 2026-04-10 | DEF 14A | avtx-20260408.htm |
| 2026-04-10 | ARS | avtx10-k2025asxfiled_wrap.pdf |
| 2026-03-27 | 8-K | avtx-20260323.htm |
| 2026-03-23 | S-8 | tm268193d1_s8.htm |
| 2026-03-23 | 10-K | avtx-20251231.htm |
| 2026-01-12 | 8-K | avtx-20260112.htm |
| 2026-01-08 | S-3 | tm261721-1_s3.htm |